Navigation Links
Intelligent Medical Devices, Inc. (IMDx) Introduces a CE-Marked Automated Assay for the Detection of C. difficile Including Hypervirulent Strains

CAMBRIDGE, Mass., Aug. 1, 2011 /PRNewswire/ -- Intelligent Medical Devices, Inc. (IMDx) today announced it has received CE-Mark for a high-throughput automated assay for the detection of C. difficile, including the A-B+ 1470 variant, as well as the NAP1 strain. The IMDx™ C. difficile assay for the Abbott m2000™ is the first assay released under a multi-year distribution agreement between Abbott and IMDx whereby IMDx will design, develop, regulatory clear, and manufacture assays for the Abbott FDA cleared m2000 instrument.

Designed utilizing IMDx's proprietary bioinformatics process, the IMDx C. difficile assay for the Abbott m2000 demonstrates a sensitivity of 95.7 percent and a specificity of 100 percent (internal comparison data).  C. difficile may develop after prolonged antibiotic use and is the most frequent cause of health-care-associated diarrhea, also causing more severe intestinal conditions such as colitis. The bacterium is easily transmitted via direct contact with high-touch surfaces in patient rooms, contaminated patient-care items, and hands of health-care workers.

"Our assays are developed to incorporate evolving clinical needs. Not only do we offer automated detection of toxigenic C. difficile genes, shortening the time needed to diagnose infections, but we also cover the detection of hypervirulent strains, including NAP1, and tcdB-variant strains, including 1470.  Early identification of pathogens is critical in improving patient healthcare, shortening hospital stays, and reducing expenses," says Alice Jacobs, MD, Chairman & CEO of IMDx.

About IMDx

Based in Cambridge, MA, IMDx ( is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.  

CONTACT: Renda Hawwa, +1-617-871-6417,

SOURCE Intelligent Medical Devices, Inc. (IMDx)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
2. Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process Have Been Completed
3. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
4. Zargis Cardioscan The Intelligent Stethoscope Now Available on
5. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
6. Elekta to Highlight Intelligent Cancer Management Solutions at 2010 AAPM Annual Meeting
7. Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests
8. Finesse Launches RemoteView OPC and BatchReport Modules for Intelligent Harmonization of Third Party Bioreactor Controllers and Analyzers with TruBio DV 4.0 Bioprocess Software
9. Precyse Announces Commercial Release of Revolutionary Intelligent Workflow Solution for Health Information Management
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ... analog distortion effect tool designed specially for Final Cut Pro X. FCPX ... looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is now ...
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target ... a “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a ... discounted price. , IguanaMed’s mission is to outfit every healer around the ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing ... December, 2015, featured apartment community: Epic. In showcasing this featured apartment community in San ... Bay Area rental market to efficiently find housing suitable to their needs by showcasing ...
(Date:11/28/2015)... San Diego, California (PRWEB) , ... November 28, ... ... cloud-based medical image exchange technology and teleradiology services, has added Chris Hafey and ... prepares to exhibit at the Radiological Society of North America (RSNA) 2015 Annual ...
(Date:11/28/2015)... ... ... Safe storage for contraceptive devices may not always be easy to find. However, ... other from Bradley Beach, New Jersey, there is an easy solution to the problem. ... NuvaRings more often than necessary. As such, it affords peace of mind and eliminates ...
Breaking Medicine News(10 mins):